SIRT2 and acute myeloid leukemia: Hao et al. demonstrated that SIRT2 deacetylase acts as an upregulator for poor prognostic KMT2A-ENL fusion, and loss of SIRT2 increases the chemosensitivity of AML cells bearing this rearrangement [72].